Skip to main content
. Author manuscript; available in PMC: 2010 Aug 1.
Published in final edited form as: Clin Pharmacol Ther. 2010 Feb 17;88(2):204–213. doi: 10.1038/clpt.2009.260

Figure 5.

Figure 5

Long-term survivors do not show evidence of neuropathology at 1 year after treatment. Neuropathological analysis was performed of the brains of the rats that were long-term survivors, at 1 year after intratumoral administration of escalating doses of HC-Ad-TetOn-Flt3L and HC-Ad-TK. Flt3L, fms-like tyrosine kinase ligand 3; HC-Ad, high-capacity adenovirus; MBP, myelin basic protein; MHC II, major histocompatibility complex II, TH, tyrosine hydroxilase; TK, thymidine kinase.